This white paper presents Malaysia as an emerging destination for Phase I, Phase II, and first-in-human clinical trials. Sponsors are increasingly looking beyond saturated Asian research hubs, and Malaysia offers accredited hospitals, GCP-compliant infrastructure, skilled investigators, cost efficiencies, and a genetically diverse population that can improve the relevance of global evidence. Government support through the Ministry of Health and Clinical Research Malaysia has streamlined sponsor engagement, site activation, and workforce development. National Phase I guidelines and regulatory accreditation by the NPRA further strengthen quality and patient safety. With growing research capabilities, faster execution, and access to underrepresented populations, Malaysia can support more incl

Join for free to read